Welcome to our dedicated page for Abbvie news (Ticker: ABBV), a resource for investors and traders seeking the latest updates and insights on Abbvie stock.
AbbVie Inc. (NYSE: ABBV) is a pharmaceutical preparation manufacturing company that regularly issues news on its medicines, research programs, collaborations and manufacturing plans. Company communications emphasize a mission to discover and deliver medicines and solutions in key therapeutic areas such as immunology, oncology, neuroscience and eye care, as well as offerings in its Allergan Aesthetics portfolio.
News about AbbVie often covers clinical and scientific developments, particularly in oncology and blood cancers. The company has reported new data at major medical meetings, including results for investigational agents like etentamig (ABBV‑383) and PVEK, and updates on approved medicines such as EPKINLY (epcoritamab-bysp) and VENCLEXTA (venetoclax). Releases may detail trial outcomes, regulatory milestones, and additional indications under investigation.
Investors and observers can also find corporate and financial updates in AbbVie’s news flow, including announcements of earnings conference calls, participation in healthcare and investor conferences, and guidance-related information that aligns with its SEC filings. The company additionally highlights strategic agreements and collaborations, such as its exclusive licensing agreement with RemeGen for the PD‑1/VEGF bispecific antibody RC148 and its voluntary agreement with the U.S. administration focused on access, affordability and U.S.-based investment.
Another recurring theme in AbbVie’s news is manufacturing and investment activity. The company has announced a definitive agreement to acquire a device manufacturing facility in Tempe, Arizona, to expand drug delivery device manufacturing for immunology and neuroscience medicines, and has referenced multi‑year commitments to U.S. R&D and capital investments. AbbVie also publishes stories on patient- and community-focused initiatives, such as the “Second Winds” film about people living with chronic lymphocytic leukemia. For readers tracking ABBV, this news stream provides insight into the company’s research pipeline, regulatory progress, capital allocation and patient engagement efforts.
AbbVie (NYSE: ABBV) will report full-year and fourth-quarter 2025 financial results on Wednesday, February 4, 2026, before the market opens. The company will host a live webcast of the earnings conference call at 8:00 a.m. Central time accessible via its investor relations site at investors.abbvie.com. An archived edition of the session will be available later that day.
AbbVie (NYSE: ABBV) will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026. Management will participate in a fireside chat at 10:15 a.m. Central time.
A live audio webcast will be accessible via AbbVie’s Investor Relations website at investors.abbvie.com, and an archived edition of the session will be available later the same day.
AbbVie (NYSE: ABBV) will present new ASH 2025 data across multiple blood cancers, including MM, FL, CLL, DLBCL, AML and AL. Key trial highlights include EPCORE FL-1 phase 3 results showing PFS HR 0.21 (79% risk reduction) and ORR 95.7% for epcoritamab+R2 vs 81.0% with R2; CLL17 fixed-duration venetoclax arms meeting non-inferiority versus ibrutinib with ~3-year PFS ≈81%; etentamig (ABBV-383) combination ORR 81% in heavily pretreated MM; and PVEK+VEN+AZA CR rate 63.3% in newly diagnosed AML unfit for intensive chemo.
Safety signals include higher grade 3/4 neutropenia and infections across several regimens; investigational agents remain under study.
AbbVie (NYSE: ABBV) will present at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025. Management will take part in a fireside chat at 7:30 a.m. Central time. A live audio webcast will be available via AbbVie's investor relations site, and an archived recording will be posted later the same day.
AbbVie (NYSE: ABBV) announced U.S. FDA approval of EPKINLY (epcoritamab-bysp) in combination with rituximab and lenalidomide (EPKINLY + R2) for adult patients with relapsed or refractory follicular lymphoma after ≥1 prior systemic therapy.
The approval follows Phase 3 EPCORE FL-1 where EPKINLY + R2 reduced risk of progression or death by 79% (HR 0.21), achieved 89% ORR and 74% complete response, and median PFS was not reached versus 11.2 months for R2. Safety was consistent with known profiles; CRS occurred in 24% (mostly Grade 1–2).
AbbVie (NYSE: ABBV) launched Second Winds, a short film about three people living with chronic lymphocytic leukemia (CLL). The film premiered on Nov 13, 2025 in Los Angeles hosted by Jesse Tyler Ferguson and is announced on Nov 14, 2025. It follows Christina, Jeff, and Alejandro and highlights resilience, community support, and quality of life.
Key cited figures: about 226,432 people with CLL in the U.S. (2022) and an estimated 23,000 new cases expected in 2025. The film is available on LA Times Studios Short Docs and AbbVie YouTube and will stream on Documentary+ in December 2025.
AbbVie (NYSE: ABBV) announced the 20 recipients of the 2025 AbbVie Migraine Career Catalyst Award™, providing each winner with $2,500 to support career development for people living with migraine. The program highlights workplace impact from migraine—noting presenteeism accounts for nearly 90% of migraine-related productivity loss—and showcases winners from diverse professions who shared stories of resilience and career disruption. The company reiterated its portfolio of three migraine treatment options and ongoing research efforts.
Allergan Aesthetics (NYSE: ABBV) will present clinical and real‑world data at the 2025 American Society for Dermatologic Surgery Annual Meeting, Nov 13–16, 2025, in Chicago. The company submitted 17 abstracts, including three oral presentations in the Cosmetic "Top Ten" session on Nov 13 highlighting Phase 3 results for first‑in‑class trenibotulinumtoxinE and a Phase 4 study of 64 units of BOTOX Cosmetic for upper facial lines.
Sessions include expert panels on hyaluronic acid fillers and a symposium on the newest BOTOX Cosmetic indication for platysma bands, plus video posters covering safety, efficacy, and patient‑reported outcomes across the portfolio.
AbbVie (NYSE:ABBV) reported third-quarter 2025 results: GAAP diluted EPS $0.10 (down 88.6%) and adjusted diluted EPS $1.86 (down 38.0%); results include an unfavorable acquired IPR&D and milestones impact of $1.50 per share. Third-quarter net revenues were $15.776 billion. Key product performance included Skyrizi $4.708B (+46.8%), Rinvoq $2.184B (+35.3%), Humira $993M (-55.4%), Botox therapeutic $985M (+16.1%), and Qulipta $288M (+64.1%). AbbVie raised full-year 2025 adjusted EPS guidance to $10.61–$10.65 (includes $2.05/share IPR&D impact YTD) and declared a 5.5% dividend increase payable Feb 17, 2026.
Allergan Aesthetics (NYSE: ABBV) announced that the seventh annual BOTOX® Cosmetic Day will be held on Wednesday, November 19, 2025, offering exclusive promotions through the Allē app.
Key offers include a BOGO $50 gift card (purchase one $50 card, receive a $50 card free) starting 9 a.m. PT on 11/19 while supplies last, and a chance to win $25,000 for Allē members who register by 11/30, book a consultation, and complete treatment by 12/12. Allē has 8 million members and supports purchases across 30,000 U.S. practices. The release reiterates BOTOX Cosmetic's FDA‑approved uses for facial lines and references clinical satisfaction data and payment-plan options through Cherry.